MIRA INFORM REPORT
|
Report No. : |
350975 |
|
Report Date : |
24.11.2015 |
IDENTIFICATION DETAILS
|
Name : |
ANUH PHARMA LIMITED |
|
|
|
|
Registered
Office : |
A-3, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai – 400018,
Maharashtra |
|
Tel. No. : |
91-22-66227575 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2015 |
|
|
|
|
Date of
Incorporation : |
19.02.1960 |
|
|
|
|
Com. Reg. No.: |
11-011586 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 41.760
Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
L24230MH1960PLC011586 |
|
|
|
|
IEC No.: |
0389021601 |
|
|
|
|
TAN No.: [Tax Deduction & Collection
Account No.] |
MUMA22404E / MUMA20261D |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACA4478P |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The Company’s Shares are Listed on
the Stock Exchanges. |
|
|
|
|
Line of Business
: |
Manufacture of pharmaceuticals, medicinal chemical and
botanical products. |
|
|
|
|
No. of Employees
: |
132 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
A (62) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 2880000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Anuh Pharma Limited (APL) is a part of Mumbai based “SK Group” of
companies is a mid-sized player in the API/bulk drug industry. Company’s manufacturing
facility is located at Boisar, Thane District. It is well established company
having fine track record. The rating reflects company’s strong financial profile of the company
underscored by its robust credit protection metrics and zero debt balance-sheet.
The company has been able to shown consistent growth of its operating income
and profitability margin along with minimal dependence on outside funding for
capital expenditure and working capital requirements. The ratings however, remain constrained by company’s high client
concentration risk, fluctuation in raw material prices and foreign exchange
rates. Trade relations are fair. Business is active. Payment terms are
reported to be regular as per commitment. In view of aforesaid, the company can be considered good for business
dealings with its usual trade terms and conditions. |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
ICRA |
|
Rating |
Long term Cash Credit = BBB+ |
|
Rating Explanation |
Have moderate degree of safety and carry moderate credit risk. |
|
Date |
June 2014 |
|
Rating Agency Name |
ICRA |
|
Rating |
Short term Non-fund based = A2+ |
|
Rating Explanation |
Have strong degree of safety and carry low credit risk. |
|
Date |
June 2014 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2015.
INFORMATION DENIED BY
|
Name : |
Mr. K. D. Dhanawade |
|
Designation : |
Not Divulged |
|
Contact No.: |
91-2525-605361 |
|
Date : |
21.11.2015 |
LOCATIONS
|
Registered / Corporate Office : |
A-3, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli,
Mumbai – 400018, Maharashtra, India |
|
Tel. No.: |
91-22-66227575/ 55527575 |
|
Fax No.: |
91-22-55527600/ 66227500 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory 1 : |
Anuh Pharma E-17/3 and 17/4, M.I.D.C.
Tarapur, Boisar, District Thane - 401506, Maharashtra, India |
|
Tel. No.: |
91-2525-272174/ 270281 |
|
Fax No.: |
91-2525-270281 |
|
E-Mail : |
|
|
|
|
|
Factory 2 : |
Eskay Fine Chemicals Turbhe Thane Belapur Road, Navi Mumbai – 400705, Maharashtra, India |
|
Telefax
: |
91-22-27681505/ 27681708 |
|
E-Mail : |
|
|
|
|
|
R & D Division : |
A-514, TTC
Industrial Area, MIDC, Mahape, Navi Mumbai – 400701, Maharashtra, India |
DIRECTORS
As on 31.03.2015
|
Name : |
Mr. Bipin Nemchand Shah |
|
Designation : |
Managing Director |
|
Address : |
180 1 Devdarshan, 50 Ridge Road, Teen Batti, Mumbai - 400 006 Maharashtra, India |
|
Date of Birth/Age : |
07.03.1949 |
|
Date of Appointment : |
01.04.2014 |
|
PAN No.: |
AACPS5406N |
|
DIN No.: |
00083244 |
|
|
|
|
Name : |
Mr. Jasvantlal Girdharilal Shah |
|
Designation : |
Chairman - Independent and Non-Executive Director |
|
Address : |
5711439, Adarsh Nagar, Prabhadevi, Dadar, Mumbai 400025 Maharashtra, India |
|
Date of Birth/Age : |
24.11.1933 |
|
Date of Appointment : |
09.08.1995 |
|
DIN No.: |
00372600 |
|
|
|
|
Name : |
Mr. Jayantilal Popatlal Shah |
|
Designation : |
Director |
|
Address : |
Flat No. 3B, 31D Floor, New Suvas A, 68-F, Nepeansea Road, Malabar Hill, Mumbai - 400 006, Maharashtra, India |
|
Date of Birth/Age : |
07.05.1929 |
|
Date of Appointment : |
29.10.1980 |
|
DIN No.: |
00083146 |
|
|
|
|
Name : |
Mr. Lalitkumar Popatlal Shah |
|
Designation : |
Director |
|
Address : |
B-212, Amalfi, 27B, L.D. Ruparel Marg, Malabar Hill, Mumbai - 400 006 Maharashtra, India |
|
Date of Birth/Age : |
02.10.1936 |
|
Date of Appointment : |
29.10.1980 |
|
DIN No.: |
00396345 |
|
|
|
|
Name : |
Mr. Bharat Nemchand Shah |
|
Designation : |
Director |
|
Address : |
4'h Floor, Room No. 15, Bhartiya Bhavan, Netaji Subhash Road, Marine Drive, Mumbai - 400 020 Maharashtra, India |
|
Date of Birth/Age : |
06.09.1946 |
|
Date of Appointment : |
29.10.1980 |
|
PAN No.: |
ADUPS8329M |
|
DIN No.: |
00083354 |
|
|
|
|
Name : |
Mr. Dilip Shah |
|
Designation : |
Director |
|
Address : |
2/21 Beach Queen, 35b Azad Road, Juhu, Mumbai- 400049 Maharashtra, India |
|
Date of Birth/Age : |
25.04.1941 |
|
Date of Appointment : |
12.09.2008 |
|
DIN No.: |
01989812 |
|
|
|
|
Name : |
Mr. Arun Todarwal |
|
Designation : |
Director |
|
Address : |
81, Shiner, 84, Nepean Sea Road, Mumbai, 400006, Maharashtra, India |
|
Date of Birth/Age : |
16.06.1957 |
|
Date of Appointment : |
16.09.2009 |
|
DIN No.: |
00020916 |
|
|
|
|
Name : |
Mr. Sandeep Madhusudan Joshi |
|
Designation : |
Director |
|
Address : |
202, Kasturi Towers 238A, LBS Marg Opposite Red Cross Bhavan Thane, Thane-400602, Maharashtra, India |
|
Date of Birth/Age : |
01.01.1961 |
|
Date of Appointment : |
02.08.2013 |
|
DIN No.: |
00516409 |
|
|
|
|
Name : |
Mr. Gulabchand Sharda |
|
Designation : |
Director |
|
Address : |
604 Swaroop Co Operative Housing Society Limited, Near Bhakti Mandir, Panchpakhadi, Thane (West), Thane-400602, Maharashtra, India |
|
Date of Birth/Age : |
20.04.1944 |
|
Date of Appointment : |
02.08.2013 |
|
PAN No.: |
AAMPS9620C |
|
DIN No.: |
06583340 |
|
|
|
|
Name : |
Ms. Rajeshree T Gor |
|
Designation : |
Director |
|
DIN No.: |
06873519 |
KEY EXECUTIVES
|
Name : |
Ms. Ashwini Ambrale |
|
Designation : |
Company Secretary |
|
|
|
|
Name : |
Mr. Darshan Rampariya |
|
Designation : |
Chief Financial Offi cer |
SHAREHOLDING PATTERN
As on 30.09.2015
|
Category of Shareholder |
Total No. of Shares |
Total Shareholding as a % of Total No. of
Shares |
|
(A) Shareholding of
Promoter and Promoter Group |
||
|
|
|
|
|
|
11059475 |
44.14 |
|
|
6672716 |
26.63 |
|
|
6624794 |
26.44 |
|
|
47922 |
0.19 |
|
|
17732191 |
70.77 |
|
|
|
|
|
Total shareholding
of Promoter and Promoter Group (A) |
17732191 |
70.77 |
|
|
|
|
|
(B) Public
Shareholding |
||
|
|
|
|
|
|
21215 |
0.08 |
|
|
21215 |
0.08 |
|
|
|
|
|
|
591905 |
2.36 |
|
|
|
|
|
Individual shareholders holding nominal share capital up to Rs.0.100 Million |
4641985 |
18.53 |
|
Individual shareholders holding nominal share capital in excess of Rs.0.100 Million |
1850223 |
7.38 |
|
|
218481 |
0.87 |
|
|
177260 |
0.71 |
|
|
38817 |
0.15 |
|
|
100 |
0.00 |
|
|
2304 |
0.01 |
|
|
7302594 |
29.15 |
|
Total Public
shareholding (B) |
7323809 |
29.23 |
|
Total (A)+(B) |
25056000 |
100.00 |
|
|
|
|
|
(C) Shares held by Custodians
and against which Depository Receipts have been issued |
|
|
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
Total (A)+(B)+(C) |
25056000 |
0.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacture of pharmaceuticals, medicinal chemical and
botanical products. |
||||||
|
|
|
||||||
|
Products : |
|
||||||
|
|
|
||||||
|
Brand Names : |
Not Available |
||||||
|
|
|
||||||
|
Agencies Held : |
Not Available |
||||||
|
|
|
||||||
|
Exports : |
Not Divulged |
||||||
|
|
|
||||||
|
Imports : |
Not Divulged |
||||||
|
|
|
||||||
|
Terms : |
|
||||||
|
Selling : |
Not Divulged |
||||||
|
|
|
||||||
|
Purchasing : |
Not Divulged |
PRODUCTION STATUS = NOT AVAILABLE
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Customers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
No. of Employees : |
132 (Approximately) |
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Bankers : |
|
|
Auditors : |
|
|
Name : |
S.I. Mogul and Company Chartered Accountants |
|
Address : |
73-B, Mittal Court, Nariman Point, Mumbai – 400021, Maharashtra, India
|
|
PAN No.: |
AAMFS7435P |
|
|
|
|
Enterprises which are
owned, or have significant influence of or are partners with Key management
personnel and their relatives |
|
CAPITAL STRUCTURE
As on 31.03.2015
Authorised Capital:
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
20000000 |
Equity Shares |
Rs. 5/- each |
Rs.100.000 Million |
Issued, Subscribed & Paid-up Capital:
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
8352000 |
Equity Shares |
Rs. 5/- each |
Rs. 41.760
Million |
Equity Shares:
|
Particulars |
As at March 31, 2015 |
|
|
Number |
Rs. In Million |
|
|
Shares outstanding at the beginning of the year |
8352000 |
41.760 |
|
Shares Issued during the year |
--- |
--- |
|
Shares bought back during the year |
--- |
--- |
|
Shares outstanding at the end of the year |
8352000 |
41.760 |
Shareholders holding more
than 5% of the Share Capital
|
Name of Shareholder (Equity Shares) |
As at March 31, 2015 |
|
|
No. of Shares held |
% of Holding |
|
|
Bharti Bipin Shah |
1,630,400 |
19.52 |
|
Bipin Nemchand Shah (HUF) |
707,850 |
8.48 |
|
Lalitkumar Popatlal Shah |
639,960 |
7.66 |
|
Bipin Nemchand Shah |
525,350 |
6.29 |
|
Prafulla Lalitkumar Shah |
456,000 |
5.46 |
The Company has only one class of Equity Shares having a par value of Rs. 5 per share. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividend in Indian rupees. The dividend proposed by the Board of Directors is subject to approval of the shareholders in the ensuing Annual General Meeting.
The shareholders of the Company had approved the sub-division of Equity Shares of the Company having nominal/face value of Rs. 10 each into Equity Shares having nominal/face value of Rs. 5 each at the Extraordinary General Meeting (“EGM”) held on June 9, 2006.
Consequently, the Authorised, Issued and Paid-up Share
Capital were divided from Rs. 10 per Equity share to Rs. 5 per Equity Share.
FINANCIAL DATA
[all figures are
in Rupees Million]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
41.760 |
41.760 |
41.760 |
|
(b) Reserves & Surplus |
967.212 |
817.053 |
714.475 |
|
(c) Money
received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending
allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
1008.972 |
858.813 |
756.235 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
0.000 |
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
0.000 |
2.446 |
2.580 |
|
(c) Other long term
liabilities |
0.000 |
0.000 |
0.000 |
|
(d) long-term
provisions |
5.822 |
2.559 |
2.135 |
|
Total Non-current
Liabilities (3) |
5.822 |
5.005 |
4.715 |
|
|
|
|
|
|
(4) Current
Liabilities |
|
|
|
|
(a) Short
term borrowings |
0.000 |
0.000 |
5.237 |
|
(b) Trade
payables |
480.108 |
600.184 |
469.542 |
|
(c) Other
current liabilities |
19.954 |
17.660 |
13.143 |
|
(d) Short-term
provisions |
167.995 |
150.928 |
112.408 |
|
Total Current
Liabilities (4) |
668.057 |
768.772 |
600.330 |
|
|
|
|
|
|
TOTAL |
1682.851 |
1632.590 |
1361.280 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1)
Non-current assets |
|
|
|
|
(a) Fixed
Assets |
|
|
|
|
(i)
Tangible assets |
93.952 |
120.550 |
104.025 |
|
(ii)
Intangible Assets |
0.961 |
0.985 |
0.773 |
|
(iii)
Capital work-in-progress |
3.304 |
1.780 |
25.980 |
|
(iv)
Intangible assets under development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
132.739 |
80.286 |
55.790 |
|
(c) Deferred tax assets (net) |
6.678 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
9.692 |
13.285 |
9.270 |
|
(e) Other
Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total Non-Current
Assets |
247.326 |
216.886 |
195.838 |
|
|
|
|
|
|
(2)
Current assets |
|
|
|
|
(a)
Current investments |
293.271 |
188.000 |
138.021 |
|
(b)
Inventories |
164.204 |
193.244 |
236.843 |
|
(c) Trade
receivables |
681.503 |
747.472 |
544.360 |
|
(d) Cash
and cash equivalents |
141.539 |
154.713 |
133.767 |
|
(e)
Short-term loans and advances |
152.711 |
129.919 |
110.035 |
|
(f) Other
current assets |
2.297 |
2.356 |
2.416 |
|
Total
Current Assets |
1435.525 |
1415.704 |
1165.442 |
|
|
|
|
|
|
TOTAL |
1682.851 |
1632.590 |
1361.280 |
PROFIT
& LOSS ACCOUNT
|
|
PARTICULARS |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
|
SALES |
|
|
|
|
|
Income |
2836.905 |
2663.977 |
2426.708 |
|
|
Other Income |
50.488 |
41.487 |
22.275 |
|
|
TOTAL |
2887.393 |
2705.464 |
2448.983 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials Consumed |
2182.162 |
2099.306 |
1968.956 |
|
|
Purchases of Stock-in-Trade |
11.741 |
8.289 |
59.411 |
|
|
Changes in inventories of
finished goods, work-in-progress and Stock-in-Trade |
21.209 |
35.146 |
(27.523) |
|
|
Employees benefits expense |
56.246 |
46.658 |
38.931 |
|
|
Other expenses |
264.193 |
242.799 |
215.271 |
|
|
TOTAL |
2535.551 |
2432.198 |
2255.046 |
|
|
|
|
|
|
|
Less |
PROFIT/
(LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION |
351.842 |
273.266 |
193.937 |
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
0.502 |
1.039 |
0.453 |
|
|
|
|
|
|
|
|
PROFIT/
(LOSS) BEFORE TAX, DEPRECIATION AND
AMORTISATION |
351.340 |
272.227 |
193.484 |
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
32.735 |
17.461 |
16.637 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
BEFORE TAX |
318.605 |
254.766 |
176.847 |
|
|
|
|
|
|
|
Less |
TAX |
98.695 |
86.869 |
51.497 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
AFTER TAX |
219.910 |
167.897 |
125.350 |
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
208.500 |
156.000 |
141.720 |
|
|
|
|
|
|
|
Add |
Income Tax
adjustment of earlier years |
(0.100) |
2.400 |
(2.500) |
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
Transfer to General Reserve |
100.000 |
50.000 |
50.000 |
|
|
Proposed final Dividend |
41.800 |
54.400 |
50.100 |
|
|
Tax on proposed final Dividend |
8.300 |
9.200 |
8.500 |
|
|
Interim Dividend |
16.700 |
10.400 |
0.000 |
|
|
BALANCE CARRIED
TO THE B/S |
258.700 |
208.500 |
156.000 |
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
F.O.B. Value of Exports |
1200.250 |
1008.041 |
983.494 |
|
|
TOTAL EARNINGS |
1200.250 |
1008.041 |
983.494 |
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
26.33 |
21.06 |
15.01 |
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
Current Maturities of Long term debt |
NA |
NA |
NA |
|
Cash generated from operations |
297.904 |
208.052 |
65.298 |
|
Net cash flows from (used in) operations |
187.903 |
145.939 |
15.838 |
QUARTERLY RESULTS
|
PARTICULARS |
30.06.2015 Unaudited 1st
Quarter |
30.09.2015 Unaudited
2nd
Quarter |
|
Net Sales |
868.140 |
914.710 |
|
Total Expenditure |
757.030 |
798.680 |
|
PBIDT (Excl OI) |
111.110 |
116.030 |
|
Other Income |
10.680 |
5.280 |
|
Operating Profit |
121.790 |
121.310 |
|
Interest |
0.010 |
0.020 |
|
Exceptional Items |
NA |
NA |
|
PBDT |
121.780 |
121.290 |
|
Depreciation |
5.050 |
5.490 |
|
Profit Before Tax |
116.730 |
115.800 |
|
Tax |
36.500 |
41.500 |
|
Provisions and contingencies |
NA |
NA |
|
Profit After Tax |
80.230 |
74.300 |
|
Extraordinary Items |
NA |
NA |
|
Prior Period Expenses |
NA |
NA |
|
Other Adjustments |
NA |
NA |
|
Net Profit |
80.230 |
74.300 |
KEY
RATIOS
|
PARTICULARS |
|
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
Net Profit Margin (PAT / Sales) |
(%) |
7.75 |
6.30 |
5.17 |
|
|
|
|
|
|
|
Operating Profit Margin (PBIDT/Sales) |
(%) |
12.40 |
10.26 |
7.99 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
20.69 |
16.43 |
13.82 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.32 |
0.30 |
0.23 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt /Networth) |
|
0.00 |
0.00 |
0.01 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.15 |
1.84 |
1.94 |
STOCK
PRICES
|
Face Value |
Rs.5/- |
|
Market Value |
Rs. 311.00/- |
FINANCIAL ANALYSIS
[all figures are
in Rupees Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Share Capital |
41.760 |
41.760 |
41.760 |
|
Reserves & Surplus |
714.475 |
817.053 |
967.212 |
|
Net
worth |
756.235 |
858.813 |
1008.972 |
|
|
|
|
|
|
long-term borrowings |
0.000 |
0.000 |
0.000 |
|
Short term borrowings |
5.237 |
0.000 |
0.000 |
|
Total
borrowings |
5.237 |
0.000 |
0.000 |
|
Debt/Equity
ratio |
0.007 |
0.000 |
0.000 |
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
2426.708 |
2663.977 |
2836.905 |
|
|
|
9.777 |
6.491 |
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
2426.708 |
2663.977 |
2836.905 |
|
Profit |
125.350 |
167.897 |
219.910 |
|
|
5.17% |
6.30% |
7.75% |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
No |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
Yes |
|
8 |
Designation of contact person |
No |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
Yes |
|
12 |
Voter Id Card No. of Proprietor / Partners |
No |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
No |
|
16 |
No. of employees |
Yes |
|
17 |
Details of sister concerns |
Yes |
|
18 |
Major suppliers |
No |
|
19 |
Major customers |
No |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
No |
|
22 |
Conduct of the banking account |
-- |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last three years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
No |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
Yes |
|
32 |
Litigations that the firm/promoter
involved in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
No |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
INDEX OF CHARGES
|
S.NO. |
CHARGE ID |
DATE OF CHARGE CREATION/MODIFICATION |
CHARGE AMOUNT SECURED |
CHARGE HOLDER |
ADDRESS |
SERVICE REQUEST NUMBER (SRN) |
|
1 |
10038218 |
22/03/2012 * |
650,000,000.00 |
BANK OF INDIA |
MUMBAI MID
CORPORATE, 70/80, M.G. ROAD,, BANK OF INDIA |
B38298881 |
|
2 |
90186656 |
20/03/1999 |
2,500,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
3 |
90186448 |
23/04/1997 |
2,000,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
4 |
90184014 |
14/06/2010 * |
450,000,000.00 |
BANK OF INDIA |
WORLI NAKA BR., PANKAJ MANSION, OPPOSITE PODAR HOSPITAL, DR. A. B. ROAD, WORLI NAKA, MUMBAI, MAHARASHTRA - 400018, INDIA |
A91194704 |
|
5 |
90185621 |
23/04/1997 * |
1,200,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
6 |
90187519 |
23/04/1997 * |
4,000,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH, M.P. MARG; HERMES HOUSE, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
7 |
90185390 |
29/07/1992 * |
3,300,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
8 |
90187464 |
06/10/1995 * |
3,300,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
9 |
90183919 |
08/02/1991 * |
4,500,000.00 |
BANK OF INDIA |
OPERA HOUSE BRANCH; HERMES HOUSE, MAMA PARAMANANDRD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
|
10 |
90187389 |
08/01/1987 |
300,000.00 |
CANARA BANK |
QUEEN'S ROAD, BOMBAY, MAHARASHTRA - 400004, INDIA |
- |
* Date of charge modification
OPERATIONS
The sales and operating income for the year ended 31st March
2015 amounted to Rs. 2814.100 Million as against Rs. 2649.300 Million for the
previous year. Thus the turnover of the Company has increased by about 6.22 %
as compared to last year’s turnover. During the year 2014-15 profit before tax
as compared to last year has increased by 25% from Rs. 254.800 Million to Rs. 318.600
Million and profit after tax has increased by 25% from Rs. 175.900 Million to
Rs. 219.900 Million
CURRENT OUTLOOK
The Company has planned to achieve a sales turnover of Rs. 3250.000 Million during the current year.
MANAGEMENT DISCUSSION AND ANALYSIS
Global Pharmaceutical Market
The global pharmaceutical market is expected to reach USD 1 trillion by 2014 and nearly USD 1.1 trillion by 2015, according to the IMS Institute for Healthcare Informatics. The market will increase at a compound annual growth rate (CAGR) of 3-6% during the next five years, slowing from the 6.2% annual growth rate that occurred during the past five years. The size of the global market for pharmaceuticals is expected to grow nearly by USD 1.3 trillion in 2020 and Indian Pharma to touch USD 45 billion in 2020 almost double from the current level.
India will be a top 3 pharma market by incremental growth by 2020 and in absolute size the country will become the 6th largest market globally by 2020. Only USA, China, Japan, Germany and Russia will be ahead of India in the global pharma.
India is home to 10,500 manufacturing units and over 3000 pharma companies. India exports all forms of pharmaceuticals from API to formulation.
Globally India ranks amongst the top exporters of formulation by volumes. India’s generic exports have been growing at a rate of nearly 24% annually over the last four years. India’s pharma exports stood at USD 14.7 billion in 2012-13 registering growth rate of 11%. India plans to increase its total exports to USD 25 billion by 2016.
India ranked 12th largest exporters of formulations in value terms and amongst top two in volume terms.
India ranked 10th largest exporters of APIs and 2nd in terms of export volume.
a) Total Indian Companies fi led DMF with USFDA – 225
b) No. of sites (Bulk Drugs + Formulation) approved by USFDA as on 30/09/2012 – 320
c) No. of DMFs (Type II Active) fi led from India as on 30/12/2013 - 3411 fi led by Indian Companies which is almost 35-40% of total DMF fi led with USA.
d) India fi led total ANDAS, as on 31/12/2013 - 2661.
e) Indian formulation companies with USFDA approval - 35.
f) Total No. of CEP received as on 31/01/2014 - 1105.
g) No. of Companies with CEPs - 155.
h) No. of molecules for which CEPs have been fi led with EDQM - 344.
i) No. of sites approved by EDQM in India as on 30/04/2013 - 353.
j) WHO-GMP certifi ed plants as per DCGI - 1270 approx.
k) USD 45 billion in revenue by 2020.
l) USD 200 billion to be spent on Healthcare Infrastructure by 2024
Global Bulk Drugs Market
Three segments - Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs account for a majority of global bulk drug consumption.
The total global bulk drug consumption is USD 120 billion out of which 80% is used for Branded Prescription drugs, 10% for OTC drugs and 10% for Generic Prescription drugs.
Anuh pharma is 151st most profitable company in the world in the space of generic pharmaceutical industry.
Indian Pharmaceutical Market
The value of production (including exports) of formulations for 2013-14 is estimated at R 1470000.000 Million, showing a growth of 14% over previous year.
The Indian domestic pharmaceutical market size is 12 billion USD in the year 2011 and is expected to grow at a high double digits till 2015.
Indian Bulk Drug Market
The size of Indian Bulk Drug market in 2011 is 12 billion USD and is projected to be worth 20 billion USD in 2015 with a CAGR of 22%. Currently 90% of the domestic bulk drug requirement is being met by the Indian industry.
India
has now emerged as the second largest producer of bulk drugs after China.
FINANCIAL PERFORMANCE
In the bygone fi the sales of Anuh Pharma Limited increased by 6.22% to R 281408.400 million from Rs.264927.900 million.
The Company generated Rs. 318.605 million in PBT as compared to Rs. 254.765 million in the previous year.
OPPORTUNITIES AND
OUTLOOK
Subject will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization.
The Company is looking at different opportunities in untapped markets and also across a value chain. It plans for alliances with business associates in the global market, giving a huge boost to the selective products that it already deals in
We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.
We will continue to focus on training and motivation of manpower so as to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.
CONTINGENT
LIABILITIES:
(Rs. in million)
|
PARTICULARS |
31.03.2015 |
|
Claims against the Company not acknowledged as deb |
0.000 |
|
Guarantees issued by the banks on behalf of the Company |
0.000 |
|
Other money for
which the Company is contingently liable: |
|
|
(1) Letter of Credit outstanding |
350.083 |
|
(2) Sales Tax |
2.703 |
|
(3) Income Tax |
0.062 |
|
|
|
|
Total |
352.848 |
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER 2015
(Rs. in million)
|
Sr. No. |
Particulars |
Quarter Ended |
Year to date ended |
|
|
30.09.2015 |
30.06.2015 |
30.09.2015 |
||
|
Unaudited |
Unaudited |
Unaudited |
||
|
Part I |
|
|
|
|
|
1. |
Net
Sales / Income from Operations |
914.712 |
868.138 |
1782.848 |
|
|
|
|
|
|
|
2. |
Expenditure |
|
|
|
|
|
a) Cost of materials
consumed |
701.439 |
698.948 |
1400.387 |
|
|
b) Purchase of
stock-in-trade |
-- |
-- |
-- |
|
|
c) Changes in inventories of finished goods,
work-in-progress and stock-in-trade |
(1748.500) |
(39.104) |
(56.588) |
|
|
d) Employee benefits
expense |
17.142 |
15.657 |
32.799 |
|
|
e) Depreciation and amortisation
expense |
5.487 |
5.050 |
10.537 |
|
|
f) Power and Fuel Charges |
10.595 |
8.636 |
19.232 |
|
|
g) Other expenses |
53.929 |
46.392 |
100.321 |
|
|
Total Expenses |
788.547 |
756.147 |
1544.694 |
|
3. |
Profit/ (Loss) from Operations before Other
Income, Exchange gain/(loss), Finance costs and Exceptional items (1-2) |
126.165 |
111.990 |
238.155 |
|
4a. |
Other Income |
5.275 |
10.679 |
15.953 |
|
4b. |
Exchange Gain / (Loss)
(Net) |
(15.622) |
(5.929) |
(12.905) |
|
5. |
Profit /(Loss) from Ordinary activities before finance costs and
Exceptional items (3+4a+4b) |
115.818 |
116.739 |
232.55 |
|
6. |
Finance
Costs |
0.017 |
0.006 |
0.023 |
|
7. |
Profit
/ (Loss) from ordinary activities after Finance costs but before Exceptional
items (5-6) |
115.801 |
116.739 |
232.557 |
|
8. |
Exceptional
items |
-- |
-- |
-- |
|
9. |
Profit/
(Loss) from ordinary activities before tax (7+8) |
115.801 |
116.739 |
232.557 |
|
10. |
Tax
expenses |
41.500 |
36.500 |
78.000 |
|
11. |
Net
Profit / (Loss) from ordinary activities after tax (9-10) |
74.301 |
80.233 |
154.534 |
|
12. |
Extraordinary items |
-- |
-- |
-- |
|
13. |
Net Profit / (Loss) for the period (11+12) |
74.301 |
80.233 |
154.534 |
|
14. |
Paid-up equity share
capital (Face Value of Rs. 5 per share) |
125.280 |
41.760 |
125.280 |
|
15. |
Reserve excluding
Revaluation reserve |
|
|
|
|
16. |
Earnings Per Share (EPS) before
and after extraordinary items (of Rs. 5/- each) a) Basic b) Diluted |
2.97 2.97 |
9.61 9.61 |
6.17 6.17 |
|
|
|
|
|
|
|
Part II |
|
|
|
|
|
A. |
PARTIULARS
OF SHAREHOLDINGS |
|
|
|
|
|
Public Shareholding |
|
|
|
|
|
- Number of Shares |
7323609 |
2400241 |
7323809 |
|
|
- Percentage of
Shareholding |
29.23 |
28.74 |
29.23 |
|
|
Promoters and Promoter Group Shareholding |
|
|
|
|
|
a) Pledged/Encumbered |
|
|
|
|
|
- Number of Shares |
Nil
|
Nil
|
Nil
|
|
|
- Percentage of Shares
(as a % of the Total Shareholding of promoter and promoter group) |
|
|
|
|
|
- Percentage of Shares
(as a % of the Total Share Capital of the Company) |
|
|
|
|
|
b) Non Encumbered |
|
|
|
|
|
- Number of Shares |
17732191 |
5951759 |
11732191 |
|
|
- Percentage of Shares
(as a % of the Total Shareholding of Promoter and Promoter Group) |
100.00 |
100.00 |
100.00 |
|
|
- Percentage of Shares
(as a % of the Total Share Capital of the Company) |
70.77 |
71.26 |
70.77 |
|
PARTICULARS |
For the quarter ended 30th SEPTEMBER 2015 |
|
B INVESTORS
COMPLAINTS |
|
|
Pending at
the beginning of the quarter |
Nil |
|
Received
during the quarter |
18 |
|
Disposed
during the quarter |
18 |
|
Remaining unresolved
at the end of the quarter |
Nil |
Note:
- The above
results were reviewed by audit committee and taken on record by the board
of director of the company at their meeting held on 7th
November 2015.
- The company’s
operation fall under single segment namely “Bulk Drugs and Chemicals”.
STANDALONE STATEMENT OF ASSETS AND LIABILITIES
(Rs. In Million)
|
Particulars |
As at 30.09.2015 |
|
|
|
Particulars |
|
|
A |
EQUITY
AND LIABILITIES |
|
|
1 |
Shareholder’s
Funds |
|
|
|
a)
Share Capital |
125.300 |
|
|
b)
Reserves & Surplus |
1038.300 |
|
|
c)
Money received against share warrants |
0.000 |
|
|
Sub
Total- Shareholders funds |
1163.600 |
|
2 |
Share
application money pending allotment |
|
|
3 |
Minority
Interest |
|
|
4 |
Non-current
liabilities |
|
|
|
(a)
Long term borrowings |
0.000 |
|
|
(b)
Other long term liabilities |
0.000 |
|
|
(c)
Long term provisions |
5.800 |
|
|
Sub
Total- Non Current Liabilities |
5.800 |
|
5 |
Current
liabilities |
|
|
|
(a)
Short term borrowings |
45.700 |
|
|
(b)
Trade Payables |
636.500 |
|
|
(c)
Other current liabilities |
45.200 |
|
|
(d)
Short term provisions |
194.600 |
|
|
Sub
Total- Current Liabilities |
922.000 |
|
|
TOTAL-EQUITY
AND LIABILITIES |
2091.400 |
|
B |
ASSETS |
|
|
1 |
Non-current
assets |
|
|
|
(a) Fixed assets |
|
|
|
(i)
Tangible Assets |
184.700 |
|
|
(ii)
Intangible Assets |
4.400 |
|
|
(iii)
Capital work-in-progress |
-- |
|
|
(iv)
Intangible assets under development |
-- |
|
|
(b)
Non-current investment |
189.100 |
|
|
(c)
Deferred tax assets (net) |
193.900 |
|
|
(d)
Long-term loans and advances |
6.700 |
|
|
(e)
Other non-current loans and advances |
9.000 |
|
|
Sub-Total-
Non-current assets |
|
|
2 |
Current
assets |
|
|
|
a)
Current Investments |
96.700 |
|
|
b)
Inventories |
291.100 |
|
|
c)
Trade Receivables |
917.500 |
|
|
d)
Cash and cash equivalents |
183.200 |
|
|
(e)
Short term loans and advances |
202.700 |
|
|
(f)
Other current assets |
1.500 |
|
|
Sub-Total-
current assets |
1692.700 |
|
|
TOTAL
ASSETS |
2091.400 |
FIXED ASSETS
Tangible Assets
· Leasehold Land
· Buildings
· Plant and Machinery
· Laboratory Equipments
· Material Storage and Handling Equipments
· Electric Installations
· Air-conditioning Equipments and Refrigerators
· Computer Hardware
· Furniture and Fixtures
· Vehicles
· Office equipment
Intangible Assets
· Computer software
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair and
reasonable and comparable to compensation paid to others for similar services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 66.35 |
|
UK Pound |
1 |
Rs. 100.66 |
|
Euro |
1 |
Rs. 70.47 |
INFORMATION DETAILS
|
Information Gathered
by : |
NYA |
|
|
|
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
JYO/PNM |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL
CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILITY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
62 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.